18F-AmBF3-TATE PET/CT

DIAGNOSTIC_TEST2 trials

Sponsors

British Columbia Cancer Agency

Conditions

Medullary Thyroid CarcinomaNeuroendocrine TumorsNeuroendocrine Tumors, NETPheochromocytoma/ParagangliomaSSTR-expressing Tumors

Unknown Phase

18F-AmBF3-TATE PET/CT for Imaging NET Patients

CompletedNCT04207762

British Columbia Cancer AgencyNeuroendocrine Tumors

Start: 2020-06-09End: 2021-01-15Updated: 2021-01-20

A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

Not yet recruitingNCT07621146

British Columbia Cancer AgencyMedullary Thyroid Carcinoma, Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma +1

Start: 2026-09-15End: 2028-03-01Target: 51Updated: 2026-06-02